Get the Stockscreener App
44.65
1.25%
0.55
Royalty Pharma Plc stock is traded at $44.65, with a volume of 3.54M.
It is up +1.25% in the last 24 hours and up +9.84% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$44.10
Open:
$44.31
24h Volume:
3.54M
Relative Volume:
0.87
Market Cap:
$19.08B
Revenue:
$2.35B
Net Income/Loss:
$1.30B
P/E Ratio:
25.53
EPS:
1.7487
Net Cash Flow:
$1.05B
1W Performance:
+7.13%
1M Performance:
+9.84%
6M Performance:
+20.29%
1Y Performance:
+42.20%
1-Day Range:
$43.95
$44.92
1-Week Range:
$41.46
$44.92
52-Week Range:
$29.66
$44.92
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
44.65 | 18.84B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Rally Mode: Should I add Phoenix Laser Systems Inc Preferred Security stock to my portfolio2025 Market Sentiment & Weekly High Momentum Picks - baoquankhu1.vn
Thrivent Financial for Lutherans Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com - Investing.com UK
C WorldWide Group Holding A S Raises Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Homestead Advisers Corp Sells 37,000 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells $10.3 million in shares - Investing.com
(RPRX) Risk Channels and Responsive Allocation - Stock Traders Daily
Royalty Pharma Set for Upcoming Dividend Payment - intellectia.ai
Royalty Pharma (NASDAQ:RPRX) CFO Sells $4,924,629.36 in Stock - MarketBeat
Terrance Coyne Sells 108,424 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Terrance Coyne Sells 20,163 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? - Finviz
AE Wealth Management LLC Lowers Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
The Best Biotech Stocks to Buy - morningstar.com
Urist Marshall, royalty pharma EVP, sells $821,810 in shares By Investing.com - Investing.com South Africa
Urist Marshall, royalty pharma EVP, sells $821,810 in shares - Investing.com
Royalty Pharma (RPRX) Stock Analysis: Analysts See 15% Upside Potential - DirectorsTalk Interviews
Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Mirae Asset Global Investments Co. Ltd. Buys 31,045 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Strs Ohio Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma (RPRX) Still Attractive After A 35% One Year Share Price Gain - Yahoo Finance
Royalty Pharma stock hits 52-week high at $41.71 By Investing.com - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at $41.71 - Investing.com
Royalty Pharma Shares Rise After UBS Upgrade - marketscreener.com
UBS Upgrades Royalty Pharma to Buy From Neutral, Adjusts Price Target to $49 From $38 - marketscreener.com
Ruffer LLP Decreases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Assessing Royalty Pharma (RPRX) Valuation After Teva Autoimmune Funding Partnership Attracts Fresh Attention - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Mitsubishi UFJ Trust & Banking Corp Sells 198,889 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cullen Frost Bankers Inc. Raises Position in Royalty Pharma PLC $RPRX - MarketBeat
(RPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer on Royalty Pharma: "It's a Terrific Company" - Finviz
84,741 Shares in Royalty Pharma PLC $RPRX Bought by Oxbow Advisors LLC - MarketBeat
Jim Cramer on Royalty Pharma: “It’s a Terrific Company” - Insider Monkey
Jim Cramer Shared His Takes on These 16 Stocks - Insider Monkey
Baillie Gifford & Co. Trims Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $2.7 million By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Coyne sells shares worth $2.7 million - Investing.com
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Smart Money: Is UAMY stock a buy or sellGDP Growth & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's - simplywall.st
How Investors May Respond To Royalty Pharma (RPRX) Dividend Hike Amid Insider Sales And Results Countdown - Yahoo Finance
Royalty Pharma (RPRX) Valuation Check After Recent Share Pullback And Strong 1 Year Return - Yahoo Finance
Patient Capital Management LLC Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Feb 02 '26 |
Sale |
42.08 |
108,424 |
4,562,905 |
30,167 |
| Coyne Terrance P. | EVP & CFO |
Feb 04 '26 |
Sale |
43.29 |
20,163 |
872,913 |
22,885 |
0.23%
5.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):